🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

TXK

MOLECULAR TARGET

TXK tyrosine kinase

UniProt: P42681NCBI Gene: 729427 compounds

TXK (TXK tyrosine kinase) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TXK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gefitinib5.67290
2erlotinib5.55256
3sb 2035804.92136
4ibrutinib4.86128
5foretinib4.3476
6tozasertib4.3375
7vandetanib4.3073
8bosutinib4.0858
9pazopanib3.6939
10neratinib3.6638
11nintedanib3.6136
12canertinib3.5333
13pelitinib3.5032
14tae 6843.4330
15fedratinib3.4029
16acalabrutinib3.2224
17lestaurtinib3.0420
18spebrutinib3.0420
19r 4062.8316
20ritlecitinib2.7715
21kw 24492.6413
22zanubrutinib2.5612
23tirabrutinib1.956
24Afatinib0.691
25Axitinib0.691
26Crizotinib0.691
27Dasatinib0.691

About TXK as a Drug Target

TXK (TXK tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented TXK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TXK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.